The Mindful Experiment
Host Dr. Vic Manzo Jr. leads a practical tour of psychedelics, with both men comparing personal experiences. Matt takes on the drug-or-medicine question directly, points to the MDMA trials for PTSD, and warns about an unregulated black market.
LISTEN
Episode summary
On The Mindful Experiment, host Dr. Vic Manzo Jr. draws Matt into a practical tour of psychedelics, with both men comparing personal experiences along the way. Matt starts where he often does, with the guided psilocybin session that reconnected him with his mother and sent him back to school. He addresses the "drug or medicine" question directly, saying these can be both, and that intention is what makes the difference. He points to the MDMA trials for treatment-resistant PTSD, where most participants no longer qualified for the diagnosis after a few sessions with therapy, and to the danger of a black market where much of what is sold as MDMA is adulterated or absent entirely.
Much of the episode works as a guided map of the medicines. Matt sorts them loosely into heart-openers like MDMA and mescaline, visual ones like psilocybin and ayahuasca, and the fast, intense head-openers like DMT and 5-MeO-DMT. When Vic recounts a two-night ayahuasca weekend, blissful the first night and far harder the second, Matt reframes the rough stretch as challenging rather than bad, and underlines how much the difficulty was part of the work. He also flags the sustainability and ownership concerns around peyote, steering people toward San Pedro as a source of mescaline.
A good portion of the conversation is genuinely practical. Matt walks through preparation, set, setting, and integration, and stresses that the integration afterward matters as much as the experience, including the advice not to make big life changes in the immediate aftermath. He offers concrete questions for anyone evaluating a retreat, like how many people will be in the session, and points to places to find trained integrators. On psilocybin he explains microdosing, the sub-perceptual range and the two common protocols, and how that differs from a full dose, along with tips like using an eye mask and a guided playlist.
They close on ketamine, the one legal option, which Matt describes as a dissociative with a roughly one-hour experience that can bring fast relief for treatment-resistant depression and acute suicidality, and that appears to start new neural growth which continues after the medicine clears. Throughout, he keeps returning to his central frame, that a psychedelic is a catalyst rather than a cure, something that shows a person what is possible and then leaves the ongoing work to them. He ties this back to the book's argument, that even people who never take one benefit from understanding these medicines well enough to shape sensible laws and access.